7.0% AND ≤
Sponsors
MERCK SHARP & DOHME PERU S.R.L.,, BRISTOL MYERS SQUIBB COMPANY,, ELI LILLY AND COMPANY, Amylin Pharmaceuticals Inc.,
Unknown Phase
A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF A SITAGLIPTIN-BASED TREATMENT PARADIGM TO A LIRAGLUTIDE-BASED TREATMENT PARADIGM IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE INADEQUATE GLYCEMIC CONTROL ON METFORMIN MONOTHERAPY
PER-015-11
Target: 38Updated: 2023-09-04
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE 3 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES WHITH INADEQUATELY CONTROLLED HYPERTENSION ON AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR (ACEI) OR ANGIOTENSIN RECEPTOR BLOCKER (ARB)
PER-047-11
Target: 36Updated: 2023-09-04
A RANDOMIZED, PLACEBO CONTROLLED CLINICAL TRAIL TO EVALUATE CARDIOVASCULAR OUTCOMES AFTER TREATMENT WITH EXENATIDE ONCE WEEKLY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
PER-070-11
Target: 151Updated: 2023-09-04